Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study

BackgroundElderly patients with primary colorectal cancer (CRC) are less frequently treated with adjuvant chemotherapy than younger patients due to concerns regarding toxicity and efficiency. We investigated how age, performance status (PS) and comorbidity influence treatment outcomes.Patients and m...

Full description

Saved in:
Bibliographic Details
Published in:ESMO open 2016, Vol.1 (5), p.e000087-e000087, Article e000087
Main Authors: Lund, C M, Nielsen, D, Dehlendorff, C, Christiansen, A B, Rønholt, F, Johansen, J S, Vistisen, K K
Format: Article
Language:English
Subjects:
adjuvant chemotherapy
colorectal cancer
comorbidity
elderly
Original Research
performance status
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BackgroundElderly patients with primary colorectal cancer (CRC) are less frequently treated with adjuvant chemotherapy than younger patients due to concerns regarding toxicity and efficiency. We investigated how age, performance status (PS) and comorbidity influence treatment outcomes.Patients and methodsA retrospective single-centre study of 529 patients with stages II–III CRC treated with adjuvant chemotherapy (5-fluorouracil/capecitabine+/÷oxaliplatin) from 2001 to 2011 at Herlev Hospital, Denmark. Baseline characteristics, chemotherapy and outcome were analysed with respect to age after adjusting for PS and comorbidity.ResultsElderly patients (>70 years) had significantly more comorbidity (p
ISSN:2059-7029
2059-7029
DOI:10.1136/esmoopen-2016-000087